MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
Fennec Pharmaceuticals Net Debt 2011-2026 | FENC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Fennec Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 17.7 M | 1.12 M | - | -30.3 M | -13.6 M | -22.8 M | -28.3 M | -3.93 M | -942 K | -2.31 M | -1.66 M | -2.3 M | -5.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.7 M | -30.3 M | -7.72 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
-459 M | $ 3.83 | 1.32 % | $ 105 M |  Schweiz |
 |
Agenus
AGEN
|
-60.8 M | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
-48.9 M | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
-133 M | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.95 | -11.63 % | $ 266 B |  Britain |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Aldeyra Therapeutics
ALDX
|
-129 M | $ 1.57 | -5.42 % | $ 94.3 M | USA |
 |
Aligos Therapeutics
ALGS
|
-132 M | $ 8.08 | 1.38 % | $ 79.9 M | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
-9.22 M | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-10.9 M | $ 1.99 | 0.81 % | $ 107 M | USA |
 |
Amgen
AMGN
|
41 B | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.29 B | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
166 M | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Annexon
ANNX
|
-136 M | $ 5.56 | 1.0 % | $ 862 M | USA |
 |
Annovis Bio
ANVS
|
-8.07 M | $ 2.56 | 12.28 % | $ 52.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.88 | -5.16 % | $ 4.8 M | China |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-130 M | $ 0.7 | -1.87 % | $ 4.58 M | USA |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Ardelyx
ARDX
|
136 M | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
argenx SE
ARGX
|
-89.9 M | $ 749.99 | 0.48 % | $ 25 B |  Niderland |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
-141 M | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Assembly Biosciences
ASMB
|
-55.8 M | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.62 | 1.82 % | $ 8.71 B |  Australia |